Anupam Rasayan Reports Strong Q1 FY27 Earnings, Achieves Global First in ETFA Commercialization

Anupam Rasayan Reports Strong Q1 FY27 Earnings, Achieves Global First in ETFA Commercialization​

Anupam Rasayan India Limited has announced its unaudited financial results for the quarter ending June 30, 2026, reflecting strong momentum and strategic advancements within its specialty chemical and CDMO platforms. The company reported significant growth across key revenue metrics, alongside achieving a major technological milestone in fluorination chemistry.

The results demonstrate sustained performance in Q1 FY27, comparing favorably against the same period last year.

Key consolidated financial highlights for the quarter are detailed below:

Technological Breakthrough and Strategic Growth​

Commenting on the quarterly performance, Anand Desai, Managing Director of Anupam Rasayan India Limited, expressed satisfaction with the results, noting that the consolidated revenue growth of 36% year-on-year reflected the execution of their strategy to build a globally integrated specialty chemicals and CDMO platform.

A key achievement during the quarter was the company becoming the first in the world to commercialize Ethyl Trifluoroacetate (ETFA) using flow chemistry, a technological advancement that significantly strengthens its capabilities in complex fluorination.

Further underscoring its expansion plans, Anupam Rasayan signed a Letter of Intent with BASQUEVOLT, S.A. for the potential long-term supply of a specialty chemical product, representing a revenue opportunity estimated at US$300 million spread over ten years.

Pharmaceutical and Market Penetration​

The company also provided an update on its pharmaceutical business development. The proposed acquisition of Bliss GVS Pharma continues according to plan following the signing of the definitive agreement. Management anticipates that this transaction will enhance the company's pharmaceutical platform by providing synergies across CDMO capabilities, product development, customer relationships, and access to regulated markets.

Looking ahead, Anupam Rasayan expressed confidence in its growth trajectory. This outlook is underpinned by a robust product pipeline and expanding opportunities within both its Performance Materials and Pharmaceuticals segments. Continued investment in technology and innovation, coupled with deeper customer engagement, positions the company for sustainable long-term value creation.

ANURAS Stock Price Movement​

As of 12:11 PM, shares of Anupam Rasayan India Limited are ticking up by 0.67%, trading at ₹1215.9 after climbing ₹8.10 in live market trading. Trading activity remains steady with 341,599 shares changing hands as the stock edges higher.